Reports have said that Beijing is speaking out against the US court that recently ordered two Chinese manufacturers of Vitamin C to pay $162 million in damages for price-fixing. The US court is now accused of infringing on Beijing’s sovereignty. A spokesman for China’s Ministry of Commerce spoke out against the US court at a press conference, arguing that the ruling was “unfair and improper” and that the accused companies were simply complying with the Chinese government’s requirements. Last week a federal court in New York ordered that North China Pharmaceutical Group Corp and one of its affiliates to pay the fine after the defendants argued that the “price-fixing cartel” found to have existed by the jury was the result of Chinese government decisions. The fines were trebled by the judge.
Featured News
California AG Defends Challenge to $110B Paramount-Warner Deal
Aug 10, 2026 by
CPI
Fox Gives DOJ More Time to Review $22 Billion Roku Acquisition
Aug 10, 2026 by
CPI
Early-Decision Admissions Face Antitrust Test as Colleges Lose Bid to End Suit
Aug 10, 2026 by
CPI
Crypto Regulation Push Raises Stakes for Competition With US Banks
Aug 10, 2026 by
CPI
South Korean Petrochemical Firms Face Price-Fixing Probe as Industry Pressures Mount
Aug 10, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Antitrust Compliance
Jul 20, 2026 by
CPI
Your Antitrust Compliance Program: A Strong Voice in Your Defense
Jul 20, 2026 by
Joe Murphy
Antitrust Compliance for the AI Pricing Era
Jul 20, 2026 by
Alejandra Uria & Andre Geverola
Race to Report: Antitrust Leniency in the Whistleblower Era
Jul 20, 2026 by
Brian R. Faerstein & Nicole H. Sprinzen
Antitrust-By-Design: Competition Compliance in Digital Markets
Jul 20, 2026 by
Marcos Drummond Malvar, Gabriela Costa Carvalho Forsman & Luciana Mendes